← Oncology Approval Tracker

FDA DECISION ·

Avzivi

bevacizumab-tnjn · Bio-Thera Solutions

Biosimilar approvalBiosimilarMultiple cancer types
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

A bevacizumab biosimilar for labeled uses in metastatic colorectal and renal cell cancer, first-line nonsquamous NSCLC, recurrent glioblastoma, persistent or recurrent or metastatic cervical cancer, and platinum-resistant recurrent ovarian, fallopian tube or primary peritoneal cancer. Specific regimens and treatment-line limits vary by use.

LAMPGEN ANALYSIS

Why it matters

This action added a biosimilar product for several established VEGF-inhibition regimens.

What research teams should watch

Reconcile the original approved indications and institutional formulary before using the biosimilar in a regimen or study.

PRIMARY RECORDS

Sources